Palantir and TeleTracking Team Up to Enhance Healthcare Operations Using AI-Driven Insights
The two companies have formed a strategic partnership with the goal of transforming how hospitals and health systems make operational decisions, ultimately creating long-term value for healthcare providers around the world.
The collaboration will integrate TeleTracking's Operations IQ platform with Palantir Technologies Inc. (NASDAQ:PLTR)'s AI-driven tools, including Foundry and AIP. This combined solution is expected to equip hospitals with near real-time, actionable insights to improve staffing efficiency, speed up decision-making, and ensure that patient needs remain the top priority.
As healthcare systems continue to face increasing demands to enhance capacity and coordination without expanding their physical footprint, this partnership represents a significant step forward. By bringing together TeleTracking's operational strengths and Palantir Technologies Inc. (NASDAQ:PLTR)'s cutting-edge technology, the two aim to usher in a new era of intelligent, scalable, and efficient healthcare delivery.
Alex Karp, CEO at Palantir Technologies Inc. (NASDAQ:PLTR) made the following comment:
'This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of—where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care.'
Palantir Technologies Inc. (NASDAQ:PLTR) is an American publicly traded company that focuses on developing software platforms designed for analyzing large volumes of data.
While we acknowledge the potential of PLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: and
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Trump trade war could still see America come off worse
It is a trade deal that will 'rebalance, but enable trade on both sides,' said Ursula von der Leyen after the EU and US struck a trade deal in Scotland. It was not the most emphatic declaration by the president of the European Commission. The trading partnership between two of the biggest markets in the world is in significantly worse shape than it was before Donald Trump was elected, but this deal is better than nothing. As part of the agreement, European exports to the US will be hit with a 15% tariff. That's better than the 30% the bloc was threatened with but it is a world away from the type of open and free trade European leaders would like. The EU had offered tariff free trade to the US just weeks before the deal was announced. Money latest: Instead, it has accepted a 15% tariff and agreed to ramp up its energy purchases from the US. The EU tariff on US imports will remain close to zero but Europe did get some important exemptions - on aviation, critical raw materials, some chemicals and some medical equipment. That being said, the bloc did not achieve a breakthrough on steel, aluminium or copper, which are still facing a 50% tariff. It means the average tariff on EU exports to the US will now rise from 1.2 % last year to 17%. There is also confusion over the status of pharmaceuticals- an important industry to Europe. Products like Ozempic, which is made in Denmark, have flooded into the US market in recent years and Donald Trump was threatening tariffs as high as 50% on the sector. It appears that pharmaceuticals will fall under the 15% bracket, even though President Trump contradicted official announcements by suggesting a deal had not yet been made on the industry. The risk is that the implementation of the deal could be beset with differences of interpretation, as has been the case with the Japan deal that Trump struck last week. It also risks fracturing solidarity between EU states, all of which have different strategic industries that rely on the US to differing degrees. Germany's BDI federation of industrial groups said: "Even a 15% tariff rate will have immense negative effects on export-oriented German industry." The VCI chemical trade association said rates were still "too high". For German carmakers, including Mercedes and BMW, there was some reprieve from the crippling 27.5% tariff imposed by Trump. The industry is Europe's top exporter to the US but the German trade body, the VDA, warned that a 15% rate would "cost the German automotive industry billions annually". Meanwhile, François Bayrou, the French Prime Minister, described the agreement as a "dark day" for the union, "when an alliance of free peoples, gathered to affirm their values and defend their interests, resolves to submission." While the deal has divided the bloc, the greater certainty it delivers is not to be snubbed at. Markets bounced on the news, even though the deal will ultimately harm economic growth. Analysts at Oxford Economics said: "We don't plan material changes to our eurozone baseline forecast of 1.1% GDP growth this year and 0.8% in 2026 in response to the EU-US trade deal. "While the effective tariff rate will end up at around 15%, a few percentage points higher than in our baseline, lower uncertainty and no EU retaliation are partial offsets." However, economists at Capital Economics, said the economic outlook had now deteriorated, with growth in the bloc likely to drop by 0.2%. Germany and Ireland could be the hardest hit. While the US appears to be the obvious winner in this negotiation, uncertainty still hangs over the US economy. Trump has not achieved his goal of "90 deals in 90 days" and, in the end, American consumers could still bear the cost through higher prices. That of course depends on how businesses share the burden of those higher costs, with the latest data suggesting that inflation is yet to rip through the US economy. While Europe determined on Sunday that a bad deal is better than no deal, some fear that the worst is yet to come for the Americans.
Yahoo
23 minutes ago
- Yahoo
Is Twist Bioscience Corp. (TWST) Nearing Profitability?
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter began with a historically poor start but gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Micro Cap Composite appreciated 15.65% net-of-fees in the second quarter but underperformed the Russell Microcap Growth Index's 20.92% return. In a highly volatile market led by high-beta and lower-quality stocks, the firm does not expect the fund to align with index performance. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Twist Bioscience Corporation (NASDAQ:TWST). Twist Bioscience Corporation (NASDAQ:TWST) manufactures and distributes synthetic DNA-based products. The one-month return of Twist Bioscience Corporation (NASDAQ:TWST) was -2.17%, and its shares lost 37.34% of their value over the last 52 weeks. On July 25, 2025, Twist Bioscience Corporation (NASDAQ:TWST) stock closed at $35.99 per share, with a market capitalization of $2.16 billion. Conestoga Capital Advisors stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its second quarter 2025 investor letter: "Twist Bioscience Corporation (NASDAQ:TWST) is a rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform that manufactures synthetic DNA by 'writing' it on a silicon chip. TWST leverages their unique technology platform to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for NGS sample preparation, and antibody libraries for drug discovery and development. Conestoga was a shareholder of TWST from 2019 to 2020 and sold due to its market cap exceeding our limit. With the weakness in healthcare, Conestoga is reinvesting. TWST's fundamentals have remained robust, management has been upgraded, and we believe they are nearing profitability." A scientist holding a test tube in the lab, surrounded by equipment used in synthetic biology and drug discovery. Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 30 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the first quarter compared to 26 in the previous quarter. In the second quarter of 2025, Twist Bioscience Corporation (NASDAQ:TWST) reported revenue of $92.8 million, reflecting an increase of 23% year-over-year. While we acknowledge the potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Twist Bioscience Corporation (NASDAQ:TWST) and shared the list of best genomics stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
